SUMMARY

For Treatment Resistant Depression

• In a clinical study of adults with treatment-resistant depression, those who took SPRAVATO and an oral antidepressant experienced greater reductions of depressive symptoms at 4 weeks compared to those who received a placebo plus an oral antidepressant.¹
  • Most of the treatment difference between the SPRAVATO and placebo groups was observed at 24 hours.
  • Between 24 hours and Day 28, both the SPRAVATO and placebo groups continued to  improve but the treatment difference between the groups generally stayed the same and did not appear to increase.

For Depressive Symptoms in Adults With Major Depressive Disorder (MDD) With Suicidal Thoughts or Actions

• In clinical studies of adults with MDD with suicidal thoughts or actions, those who took SPRAVATO and an oral antidepressant experienced a greater reduction of depressive symptoms at 24 hours compared to those who took a placebo plus an oral antidepressant.¹
  • Most of the treatment difference between the SPRAVATO and placebo groups was observed starting at 4 hours.
  • Between 4 hours after starting and Day 25, both groups continued to improve but the treatment difference between the groups generally stayed the same and did not appear to increase.
• SPRAVATO is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO is safe and effective as an anesthetic medicine.
• It is not known if SPRAVATO is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO.

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest use in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for SPRAVATO.¹